S4M1 pharm

• monoamine depleter for HD chorea
• VMAT2 inhibitor
• A/E: depression/suicidal ideation

reduce relapsing attacks in MS

• sphingosine-1-P (S1P) receptor modulator
• inhibits mvmt of lymphocytes from LN
• reduce relapsing attacks in MS
• **inc liver enzymes

• immunomodulator for relapsing attacks of MS
• alters APCs

• anti-alpha-4-integrin mab
• 2nd line tx for relapse attacks in MS
• IVq4w
• A/E: PML (use req. TOUCH program)

• inhibits glutamate release, NMDA-r blocker
• extends survival or time to tracheotomy in ALS

• non-ergotamine DA agonists
• first line tx in early onset PD

• COMT inhibitors
• prevent DA peripheral s/e by enhancing L-DOPA levels in periphery and optimizing carbidopa/L-dopa therapy

use a single DA ag alone in early tx of PD to delay the use of L-Dopa in pts <66YO (ropinirole and pramipexole)

used in combo with L-Dopa in advance PD

non-ergot DA agonist used for "off" periods for rescue of freezing moments

• novel DA agonist for early and late stage PD as well as RLS
• transdermal patch

1st gen AChE-I for delay in progression of AD

• 2nd gen AChE-I for delay in progression of AD
• Donepizil commen s/e: N/V/D, insomnia, loss of appetite

NMDA antagonist (weak), blocks damage from too much glutamate

seratonin syndrome

HTN crisis

• NMDA-r blocker, used for EtOH abuse, to reduce post-cessation craving
• shown good success when taken with naltrexone

partial ag at N-ACh-r shown to minimize withdrawal and reduce craving in smokers

• mu partial agonist (high affinity)
• often combined with naloxone to prevent IV injection, which would ppt withdrawl sx

block NMDA sites

• SNRI, non-stim used for ADHD
• can cause reversible liver injury
• not for use with ht dis, DM, or HTN

• NE and DA RI
• off label usage for ADD
• CYP450 inhibitor

gabapentin

ethosuxumide, valproate, lamotrigine

valproate and levetiracetem